ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2026
Clinical and radiological outcomes of directed treatment transitions from Gilenya
Mahi A Patel, Tom G Punnen, Kevin S Shan, Morgan C McCreary, Crystal M Wright, Shanan B Munoz, Paula Hardeman, Katy W Burgess, Benjamin M Greenberg, Lindsay A Horton and 4 more
Abstract read
In one paragraphArticle in Multiple sclerosis (Houndmills, Basingstoke, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Tom G PunnenSchool of Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0009-0000-2969-2360 Kevin S ShanSchool of Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Morgan C McCrearyDepartment of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Peter O'Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-8378-460X Crystal M WrightDepartment of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Peter O'Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Shanan B MunozDepartment of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Peter O'Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0009-0003-4747-9610 Paula HardemanDepartment of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Peter O'Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Katy W BurgessDepartment of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Peter O'Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
Benjamin M GreenbergDepartment of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Peter O'Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-2091-8201 Lindsay A HortonDepartment of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Peter O'Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-6040-1947 Peter V SguignaDepartment of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Peter O'Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0003-1825-575X Lauren M TardoDepartment of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Peter O'Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0003-0214-633X Olaf StüveDepartment of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Peter O'Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Neurology Section, Dallas Veterans Affairs Medical Center, Dallas, TX, USA.ORCID 0000-0002-0469-6872 Darin T OkudaDepartment of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX, USA; Peter O'Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-6499-1523 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
backgroundGilenya
objectiveTo quantify the clinical and radiological impact of transitioning from Gilenya
methodsRetrospective data were evaluated from a single tertiary MS care center. Time to magnetic resonance imaging (MRI) activity and clinical relapse was assessed during Gilenya
resultsThe cohort included 88 PwMS (71 female; 76 White, mean age when starting Gilenya
conclusionMeasures of disease stability appear less optimal with generic fingolimod based on serological, clinical, and radiological measures.
Indexed as
Drugs, GenericDrug SubstitutionFingolimod HydrochlorideImmunosuppressive AgentsMultiple SclerosisAdultFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedRetrospective StudiesTreatment OutcomeDrugs, GenericFingolimod HydrochlorideImmunosuppressive Agentsabsolute lymphocyte countdisease-modifying therapiesfingolimodMRIMultiple sclerosis
Identifiers
PMID41482873
PMCPMC12916866
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390